Compare Cardinal Health Inc (CAH) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs Texas Instruments Incorporated — how do they compare? Cardinal Health Inc trades at $228.87 (market cap $53.89B), while Texas Instruments Incorporated trades at $309.41 (market cap $278.08B). The key difference: Texas Instruments Incorporated is far larger — about 5.2× Cardinal Health Inc's market cap, and Texas Instruments Incorporated pays the higher dividend (1.86%). Which is the better fit depends on your goals.
| CAH | TXN | |
|---|---|---|
Market Cap | $53.89B | $278.08B |
Sector | Health | Technology |
52-Week High | $239.71 | $332.35 |
52-Week Low | $146.04 | $153.33 |
Enterprise Value | $58.87B | $287.03B |
Dividend Yield | 0.89% | 1.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $233.66, down 0.91% in the last session, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.17 surpassing expectations. Revenue reached $222.58 billion in 2025, though net margins remain thin at 0.62%. Recent news highlights growth potential in medical supplies, with earnings results for fiscal 2026 due August 11.
The outlook for CAH is positive, driven by earnings momentum and sector tailwinds, but risks include high leverage with debt-to-asset ratio at 16.09% and competitive pressures. Analyst consensus is bullish with a $248 price target, suggesting 6% upside. Investors should weigh solid operational cash flow against negative shareholder equity and investing outflows.
Texas Instruments (TXN) trades at $305.55, down 1.91% with a bearish technical signal. The company shows improving fundamentals with Q1 2026 earnings beat ($1.68 vs $1.36 expected) and revenue growth to $17.68B in 2025. Recent CFO transition to Julie Knecht and strong AI-related demand from data centers provide positive catalysts. Valuation remains elevated with P/E of 51.04 and P/S of 14.78, while maintaining strong profitability with 29.11% net margin and 32.18% ROE.
TXN presents a mixed outlook with solid fundamentals offset by premium valuation. The stock offers exposure to growing AI infrastructure demand and operational improvements, but faces risks from competitive pressures and debt levels. Analyst consensus leans bullish with $317.20 price target, though technical indicators suggest near-term caution. The current price near pivot point resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
